SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('options', 'languages', 'contentTypes', 'codeEventListeners', 'deferredRun', 'simpleCache', 'addOns', 'defaultStyleProperties', 'routeFiltersIn', 'routeFiltersOut', 'routesPublic', 'nodeTypes', 'bannedIps', 'discouragedIps', 'styles', 'displayStyles', 'userBanners', 'smilies', 'bbCode', 'threadPrefixes', 'userTitleLadder', 'reportCounts', 'moderationCounts', 'userModerationCounts', 'notices', 'userFieldsInfo')
Run Time: 0.000667
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 26 | Using where |
SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('brListenerClasses', 'brBriviumAddOns')
Run Time: 0.000190
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 2 | Using where |
SELECT *
FROM xf_brivium_addon
ORDER BY addon_id
Run Time: 0.000183
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_brivium_addon | index | | PRIMARY | 77 | | 1 | |
INSERT INTO xf_data_registry
(data_key, data_value)
VALUES
(?, ?)
ON DUPLICATE KEY UPDATE
data_value = VALUES(data_value)
Params: brBriviumAddOns, a:0:{}
Run Time: 0.000167
SELECT session_data
FROM xf_session
WHERE session_id = ?
AND expiry_date >= ?
Params: d6a904f870dda61c92e58551466b1572, 1716069549
Run Time: 0.000158
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_session | const | PRIMARY,expiry_date | PRIMARY | 34 | const | 1 | |
SELECT cache_value
FROM xf_permission_combination
WHERE permission_combination_id = ?
Params: 1
Run Time: 0.000221
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_permission_combination | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT thread.*
,
user.gender, user.avatar_date, user.gravatar,
NULL AS thread_read_date,
0 AS thread_reply_banned,
0 AS thread_is_watched,
'' AS draft_message, NULL AS draft_extra
FROM xf_thread AS thread
LEFT JOIN xf_user AS user ON
(user.user_id = thread.user_id)
WHERE thread.thread_id = ?
Params: 318265
Run Time: 0.000822
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | user | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT node.*, forum.*
,
permission.cache_value AS node_permission_cache,
NULL AS forum_read_date
FROM xf_forum AS forum
INNER JOIN xf_node AS node ON (node.node_id = forum.node_id)
LEFT JOIN xf_permission_cache_content AS permission
ON (permission.permission_combination_id = 1
AND permission.content_type = 'node'
AND permission.content_id = forum.node_id)
WHERE node.node_id = ?
Params: 25
Run Time: 0.000438
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | forum | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | node | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | permission | const | PRIMARY | PRIMARY | 35 | const,const,const | 1 | |
SELECT post.*
,
thread.*, thread.user_id AS thread_user_id, thread.username AS thread_username,
thread.post_date AS thread_post_date,
post.user_id, post.username, post.post_date,
bb_code_parse_cache.parse_tree AS message_parsed, bb_code_parse_cache.cache_version AS message_cache_version,
user.*, IF(user.username IS NULL, post.username, user.username) AS username,
user_profile.*,
user_privacy.*,
signature_parse_cache.parse_tree AS signature_parsed, bb_code_parse_cache.cache_version AS signature_cache_version,
session_activity.view_date AS last_view_date,
0 AS like_date
FROM xf_post AS post
INNER JOIN xf_thread AS thread ON
(thread.thread_id = post.thread_id)
LEFT JOIN xf_bb_code_parse_cache AS bb_code_parse_cache ON
(bb_code_parse_cache.content_type = 'post' AND bb_code_parse_cache.content_id = post.post_id)
LEFT JOIN xf_user AS user ON
(user.user_id = post.user_id)
LEFT JOIN xf_user_profile AS user_profile ON
(user_profile.user_id = post.user_id)
LEFT JOIN xf_user_privacy AS user_privacy ON
(user_privacy.user_id = post.user_id)
LEFT JOIN xf_bb_code_parse_cache AS signature_parse_cache ON
(signature_parse_cache.content_type = 'signature' AND signature_parse_cache.content_id = post.user_id)
LEFT JOIN xf_session_activity AS session_activity ON
(post.user_id > 0 AND session_activity.user_id = post.user_id AND session_activity.unique_key = CAST(post.user_id AS BINARY))
WHERE (
(post.thread_id = ? AND (post.position >= 0 AND post.position < 10) )
)
AND (post.message_state IN ('visible'))
ORDER BY post.position ASC, post.post_date ASC
Params: 318265
Run Time: 0.002207
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | Using filesort |
SIMPLE | post | ref | thread_id_post_date,thread_id_position | thread_id_post_date | 4 | const | 1 | Using index condition; Using where |
SIMPLE | bb_code_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.post_id | 1 | Using where |
SIMPLE | user | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | user_profile | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | user_privacy | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | signature_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.user_id | 1 | Using where |
SIMPLE | session_activity | eq_ref | PRIMARY | PRIMARY | 22 | xenforo.cc.post.user_id,func | 1 | Using where |
INSERT INTO xf_thread_view
(thread_id)
VALUES
(?)
Params: 318265
Run Time: 0.000089
UPDATE `xf_session` SET `expiry_date` = ? WHERE (session_id = 'd6a904f870dda61c92e58551466b1572')
Params: 1716073149
Run Time: 0.001329
INSERT INTO xf_session_activity
(user_id, unique_key, ip, controller_name, controller_action, view_state, params, view_date, robot_key)
VALUES
(?, ?, ?, ?, ?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE
ip = VALUES(ip),
controller_name = VALUES(controller_name),
controller_action = VALUES(controller_action),
view_state = VALUES(view_state),
params = VALUES(params),
view_date = VALUES(view_date),
robot_key = VALUES(robot_key)
Params: 0, , , XenForo_ControllerPublic_Thread, Index, valid, thread_id=318265, 1716069549,
Run Time: 0.000133
INSERT INTO xf_bb_code_parse_cache
(content_type, content_id, parse_tree, cache_version, cache_date)
VALUES (?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE parse_tree = VALUES(parse_tree),
cache_version = VALUES(cache_version),
cache_date = VALUES(cache_date)
Params: post, 324894, a:14:{i:0;s:336:"据外媒BGR报道,一些设计冠状病毒治疗方法的研究人员正在创造基于人工抗体的疗法,这种抗体可以中和SARS-CoV-2并防止感染。Sorrento是参与开发单克隆抗体疗法的公司之一,最近宣布其提出的一种抗体可以在实验室测试中中和新冠病毒。该制药公司透露,";i:1;a:4:{s:3:"tag";s:1:"b";s:6:"option";N;s:8:"original";a:2:{i:0;s:3:"[B]";i:1;s:4:"[/B]";}s:8:"children";a:1:{i:0;s:122:"它有第二种化合物可以在实验室条件下抑制病毒,这是一种名为STI-4398(COVIDTRAP)的蛋白质。";}}i:2;s:2:"
";i:3;a:4:{s:3:"tag";s:6:"center";s:6:"option";N;s:8:"original";a:2:{i:0;s:8:"[CENTER]";i:1;s:9:"[/CENTER]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"img";s:6:"option";N;s:8:"original";a:2:{i:0;s:5:"[IMG]";i:1;s:6:"[/IMG]";}s:8:"children";a:1:{i:0;s:90:"https://rdimg.com/proxy/https://static.cnbetacdn.com/article/2020/0606/9bc514e0aaf10df.jpg";}}}}i:4;s:2:"
";i:5;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:680:"Sorrento公司几周前宣布,其候选抗体之一可以防止新冠病毒感染细胞。该公司本又有了类似的发现,称其有第二种化合物可以在实验室测试中阻止感染。新的候选药物名为STI-4398,它将用于未来Sorrento的一款名为COVIDTRAP的药物中。它是一种专有的ACE2(血管紧张素转换酶2)-Fc融合蛋白,可以产生一种 "可溶性SARS-CoV-2病毒结合诱饵受体蛋白",可以与新型冠状病毒的S蛋白结合。其想法是阻断SARS-CoV-2与人体细胞的联系,中和感染。在不感染细胞的情况下,单个病毒副本无法自我繁殖,免疫系统可以更快地清除病原体。";}}i:6;s:2:"
";i:7;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:137:"Sorrento周五宣布,STI-4398在低浓度下完全抑制了新型冠状病毒感染非洲绿猴肾上皮细胞(VERO/E6)的能力。";}}i:8;s:2:"
";i:9;a:4:{s:3:"tag";s:6:"indent";s:6:"option";N;s:8:"original";a:2:{i:0;s:8:"[INDENT]";i:1;s:9:"[/INDENT]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:3:{i:0;s:1:"
";i:1;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:323:"“STI-4398 COVIDTRAP蛋白和STI-1499中和抗体已经在我们实验室建立的SARS-CoV-2体外细胞感染模型中显示出疗效,这些结果证明现在有理由进展到动物研究中。”Slobodan Paessler博士说:“我们计划在未来两到三个月内提交所有临床前数据进行科学发表。”";}}i:2;s:1:"
";}}}}i:10;s:2:"
";i:11;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:178:"该公司已经与美国食品和药物管理局(FDA)讨论了这种新药,并获得了STI-4398,COVIDTRAP的临床试验指导,用于治疗感染患者和预防性使用。";}}i:12;s:2:"
";i:13;a:4:{s:3:"tag";s:6:"center";s:6:"option";N;s:8:"original";a:2:{i:0;s:8:"[CENTER]";i:1;s:9:"[/CENTER]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"url";s:6:"option";s:66:"https://static.cnbetacdn.com/article/2020/0606/e6108b7e4f19277.png";s:8:"original";a:2:{i:0;s:74:"[URL='https://static.cnbetacdn.com/article/2020/0606/e6108b7e4f19277.png']";i:1;s:6:"[/URL]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"img";s:6:"option";N;s:8:"original";a:2:{i:0;s:5:"[IMG]";i:1;s:6:"[/IMG]";}s:8:"children";a:1:{i:0;s:96:"https://rdimg.com/proxy/https://static.cnbetacdn.com/thumb/article/2020/0606/e6108b7e4f19277.png";}}}}}}}, 1621686945, 1716069549
Run Time: 0.000794